Rochelle D. Schwartz-Bloom

Professor in Pharmacology & Cancer Biology

External address: 
B238 LSRC Building, Durham, NC 27710
Internal office address: 
Duke Box 3813, Durham, NC 27710
(919) 684-5181

Dr. Schwartz-Bloom is a co-principal investigator for the National Science Foundation Phase II Noyce Fellowship program.


The Schwartz-Bloom laboratory has completed 18 years of research investigating novel pharmacologic approaches to prevent neuronal death caused by cerebral ischemia associated with cardiac arrest and stroke. The group studied how GABA neurotransmission dysfunction contributes to the death of hippocampal neurons after ischemia in vivo or in vitro. Dr. Schwartz-Bloom’s research program continues now exclusively in science education, which she started in 1996. With funds provided by the Duke Provost in 2007, Dr. Schwartz-Bloom established Duke Center for Science Education, an umbrella for all Duke-related activities in science education. She coordinates Duke faculty and student interests in curriculum development, research, and outreach activities in science education for the K-16 grades. Dr. Schwartz-Bloom also directs RISE (Raising Interest in Science Education,, an office within the Department of Pharmacology and Cancer Biology, where she develops and provides novel science education curricular materials in the area of pharmacology to the K-12 and college community. One of the major programs that she developed is the Pharmacology Education Partnership (, a series of pharmacology- and drug abuse-related science education modules for high school biology and chemistry students. Testing of over 15,000 high school students has revealed that student performance in biology and chemistry improves when they use the pharmacology curriculum developed by her team. Dr. Schwartz-Bloom provides several opportunities for Duke Pharmacology graduate students and post-doctoral fellows to obtain experience in teaching.


  • Ph.D., Georgetown University 1983

Schwartz, RD, Heuschneider, G, Edgar, PP, and Cohn, JA. "cAMP analogs inhibit gamma-aminobutyric acid-gated chloride flux and activate protein kinase A in brain synaptoneurosomes." Mol Pharmacol 39.3 (March 1991): 370-375.

Navarro, HA, Seidler, FJ, Schwartz, RD, Baker, FE, Dobbins, SS, and Slotkin, TA. "Prenatal exposure to nicotine impairs nervous system development at a dose which does not affect viability or growth." Brain Res Bull 23.3 (September 1989): 187-192.

Tilson, HA, Schwartz, RD, Ali, SF, and McLamb, RL. "Colchicine administered into the area of the nucleus basalis decreases cortical nicotinic cholinergic receptors labelled by [3H]-acetylcholine." Neuropharmacology 28.8 (August 1989): 855-861.

Heuschneider, G, and Schwartz, RD. "cAMP and forskolin decrease gamma-aminobutyric acid-gated chloride flux in rat brain synaptoneurosomes." Proc Natl Acad Sci U S A 86.8 (April 1989): 2938-2942.

Schwartz, RD. "The GABAA receptor-gated ion channel: biochemical and pharmacological studies of structure and function." Biochem Pharmacol 37.18 (September 15, 1988): 3369-3375. (Review)

Suzdak, PD, Schwartz, RD, Skolnick, P, and Paul, SM. "Alcohols stimulate gamma-aminobutyric acid receptor-mediated chloride uptake in brain vesicles: correlation with intoxication potency." Brain Res 444.2 (March 22, 1988): 340-345.